News Releases
Azenta Reports Third Quarter Results for Fiscal 2024, Ended June 30, 2024

BURLINGTON, Mass., Aug. 6, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2024.

 
   

Quarter Ended

 

Dollars in millions, except per share data

 

June 30,

   

March 31,

   

June 30,

   

Change

 
   

2024

   

2024

   

2023

   

Prior Qtr

   

Prior Yr.

 

Revenue from Continuing Operations

 

$

173

   

$

159

   

$

166

     

9

%

   

4

%

Organic growth

                                   

5

%

Sample Management Solutions

 

$

81

   

$

74

   

$

75

     

9

%

   

7

%

Multiomics

 

$

64

   

$

62

   

$

64

     

2

%

   

(0)

%

B Medical Systems

 

$

29

   

$

23

   

$

27

     

25

%

   

7

%

                                         

Diluted EPS Continuing Operations

 

$

(0.12)

   

$

(2.47)

   

$

(0.04)

     

95

%

   

nm

 

Diluted EPS Total

 

$

(0.12)

   

$

(2.47)

   

$

(0.02)

     

95

%

   

nm

 
                                         

Non-GAAP Diluted EPS Continuing Operations

 

$

0.16

   

$

0.05

   

$

0.13

     

nm

     

25

%

Adjusted EBITDA - Continuing Operations

 

$

18

   

$

9

   

$

13

     

89

%

   

39

%

Adjusted EBITDA Margin - Continuing Operations

   

10.3

%

   

5.9

%

   

7.8

%

               
 

 

Management Comments

"We delivered another solid quarter with above market growth, that together with the disciplined execution of our transformation initiatives, contributed to meaningful margin expansion and increased profitability," said Steve Schwartz, President and CEO. "We are delivering not only to outsized growth, but also the operational transformation that will enable long-term scale, efficiency, and profitability for Azenta." 

Third Quarter Fiscal 2024 Results

  • Revenue was $173 million, up 4% year over year. Organic revenue, which excludes the impacts from foreign exchange, was up 5% year over year. The year-over-year revenue increase was attributable to higher Sample Management Solutions and B Medical Systems ("B Medical") revenues. The combined Sample Management Solutions and Multiomics business segments grew 4% on an organic basis.
  • Sample Management Solutions revenue was $81 million, up 7% year over year.
    • Organic revenue also grew 7%, mainly driven by higher revenues in Sample Repository Solutions and Core Products, particularly in Large-automated and Cryogenic Stores and in Consumables and Instruments.
  • Multiomics revenue was $64 million, flat year over year.
    • Organic revenue grew 1% year over year, primarily driven by growth in Gene Synthesis and Next Generation Sequencing services, offset by a year-over-year decline in Sanger sequencing revenue.
  • B Medical Systems revenue was $29 million, up 7% year over year.
    • Organic revenue grew 8% year over year. The better-than-forecasted revenue in the quarter was mainly due to additional cold chain solutions orders received during the period.

Summary of GAAP Earnings Results

  • Operating loss was $15 million. Operating margin was (8.5%), up 100 basis points year over year.
    • Gross margin was 40.0%, compared to 41.0% in the third quarter 2023, driven by higher amortization expense and transformation costs in the current period as well as purchase accounting impacts to inventory in the prior year period which did not reoccur, partially offset by higher revenue and operational efficiencies.
    • Operating expenses were $84 million, flat year over year, driven by lower research and development and selling, general and administrative expenses, offset by increased restructuring and transformation charges related to the Company's cost reduction initiatives, in addition to a benefit of $1.4 million of fair value contingent consideration adjustments related to the B Medical Systems segment recognized in the third quarter of fiscal year 2023.
  • Other income included $8.0 million of net interest income versus $11.3 million in the prior year period.
  • Diluted EPS from continuing operations was ($0.12) compared to ($0.04) in the third quarter of fiscal year 2023. 

Summary of Non-GAAP Earnings Results

  • Operating income was $5 million. Operating margin was 2.6%, an improvement of 330 basis points year over year.
    • Gross margin was 45.2%, down 40 basis points compared to the third quarter 2023.
    • Operating expense in the quarter was $74 million, down 4% year over year, primarily driven by the benefit from cost reduction actions.
    • Adjusted EBITDA was $18 million, and Adjusted EBITDA margin was 10.3%, an improvement of 260 basis points year over year.
  • Diluted EPS was $0.16, compared to $0.13 one year ago.

Cash and Liquidity as of June 30, 2024

  • The Company ended the quarter with a total balance of cash, cash equivalents, restricted cash and marketable securities of $754 million.
  • Operating cash flow was $2 million in the quarter. Capital expenditures were $7 million, and free cash flow (cash flow from operations less capital expenditures) was negative $5 million.

Share Repurchase Program Update

  • In the third quarter, the Company repurchased 4.2 million shares for $225.9 million under a 10b5-1 trading program.
  • As of June 30, 2024, the Company repurchased 25.1 million shares of common stock for $1.25 billion under the 2022 Repurchase Authorization. By the end of October 2024, the Company expects to complete the full capacity of the $1.5 billion share repurchase authorization announced in November 2022.

Guidance for Continuing Operations for Full Year Fiscal 2024

  • The Company is lowering its revenue guidance while raising its earnings guidance for fiscal year 2024:
    • Total revenue is expected to be in the range of $652 to $658 million due to the expected timing of orders in both B Medical and Sample Management Solutions.
    • Total organic revenue is expected to be in the range of down 2% to down 1% relative to fiscal year 2023.
    • Adjusted EBITDA margin expansion is expected to be approximately 300 basis points.
    • Non-GAAP diluted earnings per share is expected to be in the range of $0.30 to $0.36.

Conference Call and Webcast
Azenta management will webcast its third quarter fiscal 2024 earnings conference call today at 4:30 p.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed. 

The call will be broadcast live over the Internet and, together with presentation materials referenced on the call, will be hosted at the Investor Relations section of Azenta's website at https://investors.azenta.com/events and will be archived online on this website for convenient on-demand replay.

Regulation G Use of Non-GAAP financial Measures
The Company supplements its GAAP financial measures with certain non-GAAP financial measures to provide investors a perspective on the results of business operations, which the Company believes is comparable to the similar analyses provided by its peers. These measures are not presented in accordance with, nor are they a substitute for, U.S. generally accepted accounting principles, or GAAP. These measures should always be considered in conjunction with appropriate GAAP measures. A reconciliation of non-GAAP measures to the most nearly comparable GAAP measures is included at the end of this release following the consolidated balance sheets, statements of operations and statements of cash flows. Certain amounts in the tables that supplement the consolidated financial statements may not sum due to rounding. All percentages are calculated using unrounded amounts.

"Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934
Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. Forward-looking statements include but are not limited to statements about our revenue and earnings expectations, our ability to realize margin improvement from cost reductions, and our ability to deliver financial success in the future and otherwise related to future operating or financial performance and opportunities. Factors that could cause results to differ from our expectations include the following: our ability to reduce costs effectively; the volatility of the life sciences markets the Company serves; our possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality; the inability of customers to make payments to us when due; price competition; disputes concerning intellectual property; uncertainties in global political and economic conditions; and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release.

About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.

Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com.

AZENTA INVESTOR CONTACTS:

Yvonne Perron
Vice President, Financial Planning & Analysis and Investor Relations
ir@azenta.com 

Sherry Dinsmore
sherry.dinsmore@azenta.com 

AZENTA, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

 

(In thousands, except per share data)

 
   

Three Months Ended

   

Nine Months Ended

 
   

June 30,

   

June 30,

 
   

2024

   

2023

   

2024

   

2023

 

Revenue

                       

Products

 

$

68,763

   

$

67,296

   

$

181,173

   

$

205,011

 

Services

   

104,046

     

98,652

     

305,087

     

287,704

 

Total revenue

   

172,809

     

165,948

     

486,260

     

492,715

 

Cost of revenue

                       

Products

   

47,555

     

42,747

     

126,051

     

136,855

 

Services

   

56,198

     

55,196

     

166,256

     

160,754

 

Total cost of revenue

   

103,753

     

97,943

     

292,307

     

297,609

 

Gross profit

   

69,056

     

68,005

     

193,953

     

195,106

 

Operating expenses

                       

Research and development

   

7,913

     

8,968

     

25,113

     

25,024

 

Selling, general and administrative

   

73,833

     

75,465

     

230,723

     

241,356

 

Impairment of goodwill and intangible assets

   

     

     

115,975

     

 

Contingent consideration - fair value adjustments

   

     

(1,404)

     

     

(18,549)

 

Restructuring charges

   

2,064

     

812

     

10,528

     

3,773

 

Total operating expenses

   

83,810

     

83,841

     

382,339

     

251,604

 

Operating loss

   

(14,754)

     

(15,836)

     

(188,386)

     

(56,498)

 

Other income

                       

Interest income, net

   

8,004

     

11,347

     

27,650

     

32,406

 

Other income (expense), net

   

(282)

     

819

     

650

     

(704)

 

Loss before income taxes

   

(7,032)

     

(3,670)

     

(160,086)

     

(24,796)

 

Income tax benefit

   

(450)

     

(1,207)

     

(900)

     

(9,107)

 

Loss from continuing operations

   

(6,582)

     

(2,463)

     

(159,186)

     

(15,689)

 

Income (loss) from discontinued operations, net of tax

   

     

993

     

     

(1,943)

 

Net loss

 

$

(6,582)

   

$

(1,470)

   

$

(159,186)

   

$

(17,632)

 

Basic net loss per share:

                       

Loss from continuing operations

 

$

(0.12)

   

$

(0.04)

   

$

(2.90)

   

$

(0.23)

 

Income (loss) from discontinued operations, net of tax

   

     

0.02

     

     

(0.03)

 

Basic net loss per share

 

$

(0.12)

   

$

(0.02)

   

$

(2.90)

   

$

(0.26)

 

Diluted net loss per share:

                       

Loss from continuing operations

 

$

(0.12)

   

$

(0.04)

   

$

(2.90)

   

$

(0.23)

 

Income (loss) from discontinued operations, net of tax

   

     

0.02

     

     

(0.03)

 

Diluted net loss per share

 

$

(0.12)

   

$

(0.02)

   

$

(2.90)

   

$

(0.26)

 

Weighted average shares used in computing net loss per share:

                       

Basic

   

52,963

     

63,432

     

54,914

     

68,494

 

Diluted

   

52,963

     

63,432

     

54,914

     

68,494

 

 

AZENTA, INC.

CONSOLIDATED BALANCE SHEETS

(unaudited)

(In thousands, except share and per share data)

 
   

June 30,

   

September 30,

 
   

2024

   

2023

 
                 

Assets

               

Current assets

             

Cash and cash equivalents

 

$

336,543

   

$

678,910

 

Short-term marketable securities

   

259,296

     

338,873

 

Accounts receivable, net of allowance for expected credit losses ($6,507 and $8,057, respectively)

   

167,613

     

156,535

 

Inventories

   

115,270

     

128,198

 

Derivative asset

   

834

     

13,036

 

Prepaid expenses and other current assets

   

88,102

     

103,404

 

Total current assets

   

967,658

     

1,418,956

 

Property, plant and equipment, net

   

196,124

     

205,744

 

Long-term marketable securities

   

148,086

     

111,338

 

Long-term deferred tax assets

   

1,231

     

571

 

Goodwill

   

679,691

     

784,339

 

Intangible assets, net

   

253,475

     

294,301

 

Other assets

   

77,030

     

70,471

 

Total assets

 

$

2,323,295

   

$

2,885,720

 

Liabilities and stockholders' equity

           

Current liabilities

           

Accounts payable

 

$

39,115

   

$

35,796

 

Deferred revenue

   

33,268

     

34,614

 

Accrued warranty and retrofit costs

   

9,351

     

10,223

 

Accrued compensation and benefits

   

31,229

     

33,911

 

Accrued customer deposits

   

20,954

     

17,707

 

Accrued income taxes payable

   

11,705

     

7,378

 

Short-term operating lease liability

   

10,739

     

9,499

 

Accrued expenses and other current liabilities

   

46,213

     

61,800

 

Total current liabilities

   

202,574

     

210,928

 

Long-term deferred tax liabilities

   

58,080

     

67,301

 

Long-term operating lease liabilities

   

60,654

     

60,436

 

Other long-term liabilities

   

11,589

     

12,555

 

Total liabilities

   

332,897

     

351,220

 
               

Stockholders' equity

             

Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding

   

     

 

Common stock, $0.01 par value - 125,000,000 shares authorized, 63,941,421 shares issued and
50,395,071 shares outstanding at June 30, 2024, 71,294,247 shares issued and 57,832,378
shares outstanding at September 30, 2023

   

639

     

713

 

Additional paid-in capital

   

758,269

     

1,156,160

 

Accumulated other comprehensive loss

   

(44,895)

     

(62,426)

 

Treasury stock, at cost - 13,546,350 shares at June 30, 2024 and 13,461,869 shares at
September 30, 2023

   

(205,438)

     

(200,956)

 

Retained earnings

   

1,481,823

     

1,641,009

 

Total stockholders' equity

   

1,990,398

     

2,534,500

 

Total liabilities and stockholders' equity

 

$

2,323,295

   

$

2,885,720

 

 

AZENTA, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(In thousands)

 
   

Nine Months Ended June 30,

 
   

2024

   

2023

 

Cash flows from operating activities

               

Net loss

 

$

(159,186)

   

$

(17,632)

 

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

           

Depreciation and amortization

   

66,899

     

63,443

 

Impairment of goodwill and intangible assets

   

115,975

     

 

Non-cash write-offs of assets

   

10,745

     

 

Stock-based compensation

   

12,622

     

10,091

 

Contingent consideration adjustment

   

     

(18,549)

 

Amortization and accretion on marketable securities

   

(4,706)

     

(6,942)

 

Deferred income taxes

   

(12,478)

     

(25,149)

 

Purchase accounting impact on inventory

   

     

8,737

 

Loss on disposals of property, plant and equipment

   

297

     

37

 

Changes in operating assets and liabilities:

           

Accounts receivable

   

(10,923)

     

29,028

 

Inventories

   

11,433

     

(4,104)

 

Accounts payable

   

2,831

     

(13,193)

 

Deferred revenue

   

(1,635)

     

2,496

 

Accrued warranty and retrofit costs

   

(1,080)

     

1,412

 

Accrued compensation and tax withholdings

   

(2,825)

     

(15,830)

 

Accrued restructuring costs

   

1,125

     

311

 

Other assets and liabilities

   

7,484

     

(36,578)

 

Net cash provided by (used in) operating activities

   

36,578

     

(22,422)

 

Cash flows from investing activities

               

Purchases of property, plant and equipment

   

(25,339)

     

(29,218)

 

Purchases of marketable securities

   

(378,275)

     

(236,194)

 

Sales and maturities of marketable securities

   

431,544

     

951,504

 

Net investment hedge settlement

   

1,476

     

29,313

 

Acquisitions, net of cash acquired

   

     

(386,508)

 

Net cash provided by investing activities

   

29,406

     

328,897

 

Cash flows from financing activities

               

Payments of finance leases

   

(584)

     

(181)

 

Withholding tax payments on net share settlements on equity awards

   

     

(4,924)

 

Proceeds from Employee Stock Purchase Plan

   

1,678

     

 

Share repurchases

   

(412,755)

     

(672,116)

 

Net cash used in financing activities

   

(411,661)

     

(677,221)

 

Effects of exchange rate changes on cash and cash equivalents

   

8,495

     

65,610

 

Net decrease in cash, cash equivalents and restricted cash

   

(337,182)

     

(305,136)

 

Cash, cash equivalents and restricted cash, beginning of period

   

684,045

     

1,041,296

 

Cash, cash equivalents and restricted cash, end of period

 

$

346,863

   

$

736,160

 

Supplemental disclosures:

           

Cash paid for income taxes, net

   

6,710

     

41,064

 

Purchases of property, plant and equipment included in accounts payable and accrued expenses

 

2,203

   

2,437

 

Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets

           
             
   

June 30,

   

September 30,

 
   

2024

   

2023

 

Cash and cash equivalents of continuing operations

 

$

336,543

   

$

678,910

 

Short-term restricted cash included in prepaid expenses and other current assets

   

2,771

     

4,650

 

Long-term restricted cash included in other assets

   

7,549

     

485

 

Total cash, cash equivalents and restricted cash shown in the condensed consolidatedstatementsof cash flows

 

$

346,863

   

$

684,045

 

 

Notes on Non-GAAP Financial Measures
Non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusts the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A, non-recurring costs related to the Company's business transformation initiatives and share repurchases to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers. Management also excludes special charges and gains, such as impairment losses, gains and losses from the sale of assets, certain tax benefits and charges, as well as other gains and charges that are not representative of the normal operations of the business. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not rely on any single measure.

   

Quarter Ended

   

June 30, 2024

   

March 31, 2024

   

June 30, 2023

 
           

per diluted

           

per diluted

           

per diluted

 

Amounts in thousands, except per share data

 

$

   

share

   

$

   

share

   

$

   

share

 

Net loss from continuing operations

 

$

(6,582)

   

$

(0.12)

   

$

(136,880)

   

$

(2.47)

   

$

(2,463)

   

$

(0.04)

 

Adjustments:

                                               

Amortization of completed technology

   

6,316

     

0.12

     

6,373

     

0.11

     

4,656

     

0.07

 

Purchase accounting impact on inventory

   

     

     

     

     

2,956

     

0.05

 

Amortization of other intangible assets

   

6,621

     

0.13

     

6,654

     

0.12

     

7,522

     

0.12

 

Transformation costs (1)

   

4,255

     

0.08

     

4,446

     

0.08

     

21

     

0.00

 

Restructuring and restructuring related charges

   

2,064

     

0.04

     

7,344

     

0.13

     

812

     

0.01

 

Impairment of goodwill and intangible assets

   

     

     

115,975

     

2.09

     

     

 

Contingent consideration - fair value adjustments

   

     

     

     

     

(1,404)

     

(0.02)

 

Merger and acquisition costs and costs related to share repurchase (2)

   

74

     

0.00

     

426

     

0.01

     

219

     

0.00

 

Tax adjustments (3)

   

(9)

     

(0.00)

     

1,659

     

0.03

     

(31)

     

(0.00)

 

Tax effect of adjustments

   

(4,000)

     

(0.09)

     

(3,200)

     

(0.06)

     

(3,947)

     

(0.06)

 

Non-GAAP adjusted net income from continuing operations

 

$

8,739

   

$

0.16

   

$

2,797

   

$

0.05

   

$

8,341

   

$

0.13

 

Stock based compensation, pre-tax

   

3,818

     

0.07

     

5,602

     

0.10

     

3,995

     

0.06

 

Tax rate

   

15

%

   

     

15

%

   

     

15

%

   

 

Stock-based compensation, net of tax

   

3,245

     

0.07

     

4,762

     

0.09

     

3,396

     

0.05

 

Non-GAAP adjusted net income excluding stock-based
compensation - continuing operations

 

$

11,984

   

$

0.23

   

$

7,559

   

$

0.14

   

$

11,737

   

$

0.18

 
                                                 

Shares used in computing non-GAAP diluted net income per share

   

     

52,963

     

     

55,440

     

     

63,432

 

  

   

Nine Months Ended

 
   

June 30, 2024

   

June 30, 2023

 
           

per diluted

           

per diluted

 

Amounts in thousands, except per share data

 

$

   

share

   

$

   

share

 

Net loss from continuing operations

 

$

(159,186)

   

$

(2.90)

   

$

(15,689)

   

$

(0.23)

 

Adjustments:

                               

Amortization of completed technology

   

18,315

     

0.33

     

13,725

     

0.20

 

Purchase accounting impact on inventory

   

     

     

8,737

     

0.13

 

Amortization of other intangible assets

   

20,136

     

0.37

     

22,403

     

0.33

 

Transformation costs(1)

   

8,742

     

0.16

     

(34)

     

(0.00)

 

Restructuring and restructuring related charges

   

10,528

     

0.19

     

3,773

     

0.06

 

Impairment of goodwill and intangible assets

   

115,975

     

2.11

     

     

 

Contingent consideration - fair value adjustments

   

     

     

(18,549)

     

(0.27)

 

Merger and acquisition costs and costs related to share repurchase (2)

   

4,821

     

0.09

     

12,075

     

0.18

 

Indemnification asset release

   

     

     

(19)

     

(0.00)

 

Tax adjustments (3)

   

3,508

     

0.06

     

(1,411)

     

(0.02)

 

Tax effect of adjustments

   

(9,888)

     

(0.18)

     

(11,881)

     

(0.17)

 

Non-GAAP adjusted net income from continuing operations

 

$

12,951

   

$

0.24

   

$

13,130

   

$

0.19

 

Stock-based compensation, pre-tax

   

12,622

     

0.23

     

10,091

     

0.15

 

Tax rate

   

15

%

   

     

15

%

   

 

Stock-based compensation, net of tax

   

10,729

   

$

0.20

     

8,577

   

$

0.13

 

Non-GAAP adjusted net income excluding stock-based
compensation - continuing operations

 

$

23,680

   

$

0.43

   

$

21,707

   

$

0.32

 
                                 

Shares used in computing non-GAAP diluted net income per share

   

     

54,914

     

     

68,494

 
   

(1)

Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan, and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process & systems re-design.

(2)

Includes expenses related to governance-related matters.

(3)

Tax adjustments during all periods include adjustments to tax benefits related to stock compensation. These adjustments are recognized in the period of vesting for US GAAP but included in the annual effective tax rate for Non-GAAP reporting. Tax adjustments for the nine months ended June 30, 2024 exclude the impact of recording valuation allowance adjustments against U.S. and foreign deferred tax assets in the amount of $2.4M and tax adjustments for the nine months ended June 30, 2023 exclude a $1.3M US GAAP tax benefit related to an incentive tax rate change in China.

 

   

Quarter Ended

   

Nine Months Ended

 
   

June 30,

   

March 31,

   

June 30,

   

June 30,

   

June 30,

 

Dollars in thousands

 

2024

   

2024

   

2023

   

2024

   

2023

 

GAAP net loss

 

$

(6,582)

   

$

(136,880)

   

$

(1,470)

   

$

(159,186)

   

$

(17,632)

 

Less: Income (loss) from discontinued operations

   

     

     

993

     

     

(1,943)

 

GAAP net loss from continuing operations

   

(6,582)

     

(136,880)

     

(2,463)

     

(159,186)

     

(15,689)

 

Adjustments:

                                       

Less: Interest income, net

   

(8,004)

     

(9,565)

     

(11,347)

     

(27,650)

     

(32,406)

 

Add / Less: Income tax (benefit) expense

   

(450)

     

(260)

     

(1,207)

     

(900)

     

(9,107)

 

Add: Depreciation

   

9,749

     

9,321

     

9,126

     

28,446

     

27,315

 

Add: Amortization of completed technology

   

6,316

     

6,373

     

4,656

     

18,315

     

13,725

 

Add: Amortization of other intangible assets

   

6,621

     

6,654

     

7,522

     

20,136

     

22,403

 

Earnings before interest, taxes, depreciation and
amortization - Continuing operations

 

$

7,650

   

$

(124,357)

   

$

6,287

   

$

(120,839)

   

$

6,241

 

  

   

Quarter Ended

   

Nine Months Ended

 
   

June 30,

   

March 31,

   

June 30,

   

June 30,

   

June 30,

 

Dollars in thousands

 

2024

   

2024

   

2023

   

2024

   

2023

 

Earnings before interest, taxes, depreciation and
amortization - Continuing operations

 

$

7,650

   

$

(124,357)

   

$

6,287

   

$

(120,839)

   

$

6,241

 

Adjustments:

                                       

Add: Stock-based compensation

   

3,818

     

5,602

     

3,995

     

12,622

     

10,091

 

Add: Purchase accounting impact on inventory

   

     

     

2,956

     

     

8,737

 

Add: Restructuring and restructuring related charges

   

2,064

     

7,344

     

812

     

10,528

     

3,773

 

Add: Merger and acquisition costs and costs related to
share repurchase(1)

   

74

     

426

     

219

     

4,821

     

12,075

 

Add: Impairment of goodwill and intangible assets

   

     

115,975

     

     

115,975

     

 

Less: Contingent consideration - fair value adjustments

   

     

     

(1,404)

     

     

(18,549)

 

Less: Transformation costs(2)

   

4,255

     

4,446

     

21

     

8,742

     

(34)

 

Less: Indemnification asset release

   

     

     

     

     

(19)

 

Adjusted earnings before interest, taxes, depreciation and
amortization - Continuing operations

 

$

17,861

   

$

9,436

   

$

12,886

   

$

31,849

   

$

22,315

 
   

(1)

Includes expenses related to governance-related matters.

(2)

Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan, and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process & systems re-design.

 

   

Quarter Ended

 

Dollars in thousands

 

June 30, 2024

   

March 31, 2024

   

June 30, 2023

 

GAAP gross profit

 

$

69,056

     

40.0

%

 

$

63,385

     

39.8

%

 

$

68,005

     

41.0

%

Adjustments:

                                               

Amortization of completed technology

   

6,316

     

3.7

%

   

6,373

     

4.0

%

   

4,656

     

2.8

%

Purchase accounting impact on inventory

   

     

     

     

     

2,956

     

1.8

%

Transformation costs(1)

   

2,656

     

1.5

%

   

710

     

0.4

%

   

     

 

Non-GAAP adjusted gross profit

 

$

78,028

     

45.2

%

 

$

70,468

     

44.3

%

 

$

75,617

     

45.6

%

 

   

Nine Months Ended

 

Dollars in thousands

 

June 30, 2024

   

June 30, 2023

 

GAAP gross profit

 

$

193,953

     

39.9

%

 

$

195,106

     

39.6

%

Adjustments:

                               

Amortization of completed technology

   

18,315

     

3.8

%

   

13,725

     

2.8

%

Purchase accounting impact on inventory

   

     

     

8,737

     

1.8

%

Transformation costs(1)

   

3,365

     

0.7

%

   

     

 

Non-GAAP adjusted gross profit

 

$

215,633

     

44.3

%

 

$

217,568

     

44.2

%

   

(1)

Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan, and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process & systems re-design.

 

   

Sample Management Solutions

   

Multiomics

 
   

Quarter Ended

   

Quarter Ended

 
   

June 30,

   

March 31,

   

June 30,

   

June 30,

   

March 31,

   

June 30,

 

Dollars in thousands

 

2024

   

2024

   

2023

   

2024

   

2024

   

2023

 

GAAP gross profit

 

$

36,279

     

45.0

%

 

$

32,943

     

44.4

%

 

$

34,930

     

46.4

%

 

$

29,199

     

45.9

%

 

$

27,721

     

44.6

%

 

$

28,294

     

44.3

%

Adjustments:

                                                                                               

Amortization of completed technology

   

1,010

     

1.3

%

   

1,027

     

1.4

%

   

744

     

1.0

%

   

1,038

     

1.6

%

   

1,040

     

1.7

%

   

1,220

     

1.9

%

Transformation costs(1)

   

(127)

     

(0.2)

%

   

359

     

0.5

%

   

     

     

     

     

     

     

     

 

Non-GAAP adjusted gross profit

 

$

37,162

     

46.1

%

 

$

34,329

     

46.3

%

 

$

35,674

     

47.4

%

 

$

30,237

     

47.5

%

 

$

28,761

     

46.2

%

 

$

29,514

     

46.2

%

 

   

B Medical Systems

   

Segment Total

 
   

Quarter Ended

   

Quarter Ended

 
   

June 30,

   

March 31,

   

June 30,

   

June 30,

   

March 31,

   

June 30,

 

Dollars in thousands

 

2024

   

2024

   

2023

   

2024

   

2024

   

2023

 

GAAP gross profit

 

$

3,578

     

12.5

%

 

$

2,721

     

11.9

%

 

$

4,781

     

17.9

%

 

$

69,056

     

40.0

%

 

$

63,385

     

39.8

%

 

$

68,005

     

41.0

%

Adjustments:

                                                                                               

Amortization of completed technology

   

4,268

     

15.0

%

   

4,306

     

18.9

%

   

2,692

     

10.1

%

   

6,316

     

3.7

%

   

6,373

     

4.0

%

   

4,656

     

2.8

%

Purchase accounting impact on inventory

   

     

     

     

     

2,956

     

11.0

%

   

     

     

     

     

2,956

     

1.8

%

Transformation costs(1)

   

2,783

     

9.8

%

   

351

     

1.5

%

   

     

     

2,656

     

1.5

%

   

710

     

0.4

%

   

     

 

Non-GAAP adjusted gross profit

 

$

10,629

     

37.3

%

 

$

7,378

     

32.4

%

 

$

10,429

     

39.0

%

 

$

78,028

     

45.2

%

 

$

70,468

     

44.3

%

 

$

75,617

     

45.6

%

 

   

Sample Management Solutions

   

Multiomics

 
   

Nine Months Ended

   

Nine Months Ended

 

Dollars in thousands

 

June 30, 2024

   

June 30, 2023

   

June 30, 2024

   

June 30, 2023

 

GAAP gross profit

 

$

102,494

     

43.8

%

 

$

94,509

     

42.6

%

 

$

85,391

     

45.3

%

 

$

83,013

     

44.4

%

Adjustments:

                                                               

Amortization of completed technology

   

2,853

     

1.2

%

   

2,106

     

0.9

%

   

3,117

     

1.7

%

   

3,661

     

2.0

%

Transformation costs(1)

   

231

     

0.1

%

   

     

     

     

     

     

 

Non-GAAP adjusted gross profit

 

$

105,578

     

45.2

%

 

$

96,615

     

43.6

%

 

$

88,508

     

46.9

%

 

$

86,674

     

46.3

%

 

   

B Medical Systems

   

Segment Total

 
   

Nine Months Ended

   

Nine Months Ended

 

Dollars in thousands

 

June 30, 2024

   

June 30, 2023

   

June 30, 2024

   

June 30, 2023

 

GAAP gross profit

 

$

6,068

     

9.5

%

 

$

17,584

     

21.0

%

 

$

193,953

     

39.9

%

 

$

195,106

     

39.6

%

Adjustments:

                                                               

Amortization of completed technology

   

12,345

     

19.3

%

   

7,957

     

9.5

%

   

18,315

     

3.8

%

   

13,724

     

2.8

%

Purchase accounting impact on inventory and contracts acquired

   

     

     

8,737

     

10.4

%

   

     

     

8,737

     

1.8

%

Transformation costs(1)

   

3,134

     

4.9

%

   

     

     

3,365

     

0.7

%

   

     

 

Non-GAAP adjusted gross profit

 

$

21,547

     

33.7

%

 

$

34,278

     

41.0

%

 

$

215,633

     

44.3

%

 

$

217,567

     

44.2

%

   

(1)

Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan, and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process & systems re-design.

 

 

 

   

Sample Management Solutions

   

Multiomics

   

B Medical Systems

 
   

Quarter Ended

   

Quarter Ended

   

Quarter Ended

 
   

June 30,

   

March 31,

   

June 30,

   

June 30,

   

March 31,

   

June 30,

   

June 30,

   

March 31,

   

June 30,

 

Dollars in thousands

 

2024

   

2024

   

2023

   

2024

   

2024

   

2023

   

2024

   

2024

   

2023

 

GAAP operating (loss) profit

 

$

2,469

   

$

(3,005)

   

$

70

   

$

(1,768)

   

$

(4,006)

   

$

(4,632)

   

$

(5,142)

   

$

(5,810)

   

$

(4,129)

 

Adjustments:

                                                                       

Amortization of completed technology

   

1,010

     

1,027

     

744

     

1,038

     

1,040

     

1,220

     

4,268

     

4,306

     

2,692

 

Purchase accounting impact on inventory

   

     

     

     

     

     

     

     

     

2,956

 

Amortization of other intangible assets

   

51

     

52

     

(1)

     

     

     

     

     

     

1

 

Transformation costs(1)

   

(127)

     

359

     

     

     

     

     

2,783

     

351

     

 

Other adjustment

   

1

     

     

     

     

     

     

     

     

 

Non-GAAP adjusted operating (loss) profit

 

$

3,404

   

$

(1,567)

   

$

813

   

$

(730)

   

$

(2,966)

   

$

(3,412)

   

$

1,908

   

$

(1,153)

   

$

1,520

 

 

   

Total Segments

   

Corporate

   

Total

 
   

Quarter Ended

   

Quarter Ended

   

Quarter Ended

 
   

June 30,

   

March 31,

   

June 30,

   

June 30,

   

March 31,

   

June 30,

   

June 30,

   

March 31,

   

June 30,

 

Dollars in thousands

 

2024

   

2024

   

2023

   

2024

   

2024

   

2023

   

2024

   

2024

   

2023

 

GAAP operating loss

 

$

(4,441)

   

$

(12,821)

   

$

(8,691)

   

$

(10,313)

   

$

(134,134)

   

$

(7,145)

   

$

(14,754)

   

$

(146,955)

   

$

(15,836)

 

Adjustments:

                                                                       

Amortization of completed technology

   

6,316

     

6,373

     

4,656

     

     

     

     

6,316

     

6,373

     

4,656

 

Purchase accounting impact on inventory

   

     

     

2,956

     

     

     

     

     

     

2,956

 

Amortization of other intangible assets

   

51

     

52

     

     

6,570

     

6,602

     

7,522

     

6,621

     

6,654

     

7,522

 

Transformation costs(1)

   

2,656

     

710

     

     

1,599

     

3,736

     

21

     

4,255

     

4,446

     

21

 

Restructuring charges

   

     

     

     

2,064

     

7,344

     

812

     

2,064

     

7,344

     

812

 

Impairment of goodwill and intangible assets

   

     

     

     

     

115,975

     

     

     

115,975

     

 

Contingent consideration adjustment

   

     

     

     

     

     

(1,404)

     

     

     

(1,404)

 

Merger and acquisition costs and costs related to share repurchase (2)

   

     

     

     

74

     

426

     

219

     

74

     

426

     

219

 

Other adjustment

   

     

     

     

(1)

     

     

(2)

     

(1)

     

     

(2)

 

Non-GAAP adjusted operating (loss) profit

 

$

4,582

   

$

(5,686)

   

$

(1,079)

   

$

(7)

   

$

(51)

   

$

23

   

$

4,575

   

$

(5,737)

   

$

(1,056)

 

 

   

Sample Management
Solutions

   

Multiomics

   

B Medical Systems

 
   

Nine Months Ended

   

Nine Months Ended

   

Nine Months Ended

 

Dollars in thousands

 

June 30,

   

June 30,

   

June 30,

   

June 30,

   

June 30,

   

June 30,

 
   

2024

   

2023

   

2024

   

2023

   

2024

   

2023

 

GAAP operating loss

 

$

(2,259)

   

$

(10,627)

   

$

(10,264)

   

$

(14,150)

   

$

(19,133)

   

$

(13,604)

 

Adjustments:

                                               

Amortization of completed technology

   

2,853

     

2,106

     

3,117

     

3,661

     

12,345

     

7,957

 

Purchase accounting impact on inventory

   

     

     

     

     

     

8,737

 

Amortization of other intangibles

   

154

     

259

     

     

     

     

1,366

 

Transformation costs(1)

   

231

     

     

     

     

3,134

     

 

Other adjustment

   

2

     

1

     

     

2

     

     

 

Non-GAAP adjusted operating (loss) profit

 

$

981

   

$

(8,261)

   

$

(7,147)

   

$

(10,487)

   

$

(3,654)

   

$

4,456

 

 

   

Total Segments

   

Corporate

   

Total

 
   

Nine Months Ended

   

Nine Months Ended

   

Nine Months Ended

 

Dollars in thousands

 

June 30,

   

June 30,

   

June 30,

   

June 30,

   

June 30,

   

June 30,

 
   

2024

   

2023

   

2024

   

2023

   

2024

   

2023

 

GAAP operating loss

 

$

(31,656)

   

$

(38,381)

   

$

(156,730)

   

$

(18,117)

   

$

(188,386)

   

$

(56,498)

 

Adjustments:

                                               

Amortization of completed technology

   

18,315

     

13,724

     

     

1

     

18,315

     

13,725

 

Purchase accounting impact on inventory

   

     

8,737

     

     

     

     

8,737

 

Amortization of other intangibles

   

154

     

1,625

     

19,982

     

20,778

     

20,136

     

22,403

 

Transformation costs(1)

   

3,365

     

     

5,377

     

(34)

     

8,742

     

(34)

 

Restructuring and restructuring related charges

   

     

     

10,528

     

3,773

     

10,528

     

3,773

 

Impairment of goodwill and intangible assets

   

     

     

115,975

     

     

115,975

     

 

Contingent consideration - fair value adjustments

   

     

     

     

(18,549)

     

     

(18,549)

 

Merger and acquisition costs and costs related to share repurchase (2)

   

     

     

4,821

     

12,075

     

4,821

     

12,075

 

Other adjustment

   

2

     

3

     

(1)

     

(3)

     

1

     

 

Non-GAAP adjusted operating loss

 

$

(9,820)

   

$

(14,292)

   

$

(48)

   

$

(76)

   

$

(9,868)

   

$

(14,368)

 
   

(1)

Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan, and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process & systems re-design.

(2)

Includes expenses related to governance-related matters.

 

   

Sample
Management
Solutions

   

Multiomics

   

B Medical
Systems

   

Azenta Total

 
   

Quarter Ended

   

Quarter Ended

   

Quarter Ended

   

Quarter Ended

 
   

June 30,

   

June 30,

           

June 30,

   

June 30,

           

June 30,

   

June 30,

           

June 30,

   

June 30,

         

Dollars in millions

 

2024

   

2023

   

Change

   

2024

   

2023

   

Change

   

2024

   

2023

   

Change

   

2024

   

2023

   

Change

 

Revenue

 

$

81

   

$

75

     

7

%

 

$

64

   

$

64

     

(0)

%

 

$

29

   

$

27

     

7

%

 

$

173

   

$

166

     

4

%

Acquisitions/
divestitures

   

     

     

     

     

     

     

     

     

     

     

     

 

Currency exchange
rates

   

(0)

     

     

0

%

   

(1)

     

     

1

%

   

(0)

     

     

1

%

   

(1)

     

     

1

%

Organic revenue

 

$

81

   

$

75

     

7

%

 

$

64

   

$

64

     

1

%

 

$

29

   

$

27

     

8

%

 

$

174

   

$

166

     

5

%

 

   

Sample
Management
Solutions

   

Multiomics

   

B Medical
Systems

   

Azenta Total

 
   

Nine Months Ended

   

Nine Months Ended

   

Nine Months Ended

   

Nine Months Ended

 
   

June 30,

   

June 30,

           

June 30,

   

June 30,

           

June 30,

   

June 30,

           

June 30,

   

June 30,

         

Dollars in millions

 

2024

   

2023

   

Change

   

2024

   

2023

   

Change

   

2024

   

2023

   

Change

   

2024

   

2023

   

Change

 

Revenue

 

$

234

   

$

222

     

5

%

 

$

189

   

$

187

     

1

%

 

$

64

   

$

84

     

(24)

%

 

$

486

   

$

493

     

(1)

%

Acquisitions/
divestitures

   

1

     

     

(1)

%

   

     

     

     

     

     

     

1

     

     

(0)

%

Currency exchange
rates

   

2

     

     

(1)

%

   

(1)

     

     

1

%

   

1

     

     

(1)

%

   

1

     

     

(0)

%

Organic revenue

 

$

231

   

$

222

     

4

%

 

$

190

   

$

187

     

1

%

 

$

63

   

$

84

     

(24)

%

 

$

484

   

$

493

     

(2)

%

 

Azenta logo (PRNewsfoto/Azenta)

 

SOURCE Azenta

©2024 Azenta, Inc. All rights reserved. | Privacy & Security Policy
Loading data...